Archive | Redefining Early Stage Investments (RESI) RSS feed for this section

AI Diagnostics from Oncology, Cardio, and Beyond – Interview with Jonathan Cohen, JD, Founder & CEO of 20/20 Gene Systems

19 Oct

By Erika Wu, Business Development Representative, LSN

Past RESI AI panelist, Jonathan Cohen returns to give an update on 20/20 Gene Systems, including an expansion from cancer detection to respiratory and cardiovascular diagnostics. Learn how Jonathan and the team are using Artificial Intelligence (AI) to expand their offerings, and how they’re working to create more opportunities for early-stage diagnostic startups. Digital RESI November (16-18th) returns with dynamic panels, as well as opportunities to pitch to a live panel of investors. Learn more about how you can get involved and tell your story at November’s Innovator’s Pitch Challenge!


Come for the Pitch, Stay for the Relationship

14 Oct

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN


Bright-eyed entrepreneurs with big ideas and even bigger fundraising needs have joined Digital RESI throughout 2021 in hopes of meeting investors who are just as excited to meet them, and there’s no virtual meeting spot that brings the two together like the Innovator’s Pitch Challenge (IPC). Apply to pitch at DIgital RESI November by October 22!

The IPC provides opportunities for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. Fundraising entrepreneurs use the IPC for exposure, connection, valuable feedback, and often, a conversation that leads to many more down the road. Investors use it for the same – the opportunity to hear from and connect with entrepreneurs, learn more about exciting technology, and advance deal-flow initiatives.

For these reasons, the IPC is one of the most popular and well-attended features of the Digital RESI conference series, but don’t take our word for it. See what investors have said about their participation and check out previous investors that have sat on IPC judging panels throughout 2021.

“It was a very economical use of time; the investors got to ask their important questions and the Innovators got a good idea of the most pressing questions from the investors point of view.”
William Kuziel, MedPro Investors
“The Pitch Sessions are a great opportunity to connect with startup CEOs and learn more about their work…It really has been an effective and efficient way to make connections, create deal flow and help startups raise money for their upcoming raises.”
Mayank Taneja, OSF Healthcare
“I look forward to LSN’s events because they provide an opportunity for our venture capital firm to find promising companies with exceptional technologies. The organization and technology platform make it very easy to hear numerous pitches from founders.”
Nat Brinn, VC23
“The Pitch Sessions were a great opportunity to engage with the CEO/Founders of very innovative Life Science startups. Despite the COVID-related transition from in-person to virtual meetings, the RESI team did an outstanding job organizing these sessions, ensuring that the live Q&A was very productive, and facilitating follow-up with these exciting companies.”
Gary Gershony, Life Science Angels / BayMed Venture Partners
Previous 2021 Investor Judges
Hamzeh Abdul-Hadi
Hikma Ventures
Aiden Aceves
Vida Ventures
Nuno Afonso
Apogee Ventures
Brent Ahrens
Canaan Partners
Alexandra Amen
Richard Anders
Mass Medical Angels
Bauke Anninga
M Ventures
Marc Appel
Orange Grove Bio
Anjan Aralihalli
CTI Life Sciences Fund
Aimee Barkway
Hadean Ventures
Amine Benmoussa
Apogee Ventures
Attila Berces
Sascha Berger
TVM Capital Life Science
Randy Berholtz
Mesa Verde Venture Partners
Reetika Bhardwaj
ARCH Venture Partners
Ivneet Bhullar
Fusion Fund
Yoann Bonnamour
Mérieux Equity Partners
Todd Brady
Brace Pharma Capital
Nat Brinn
Ivan Burkov
INKEF Capital
Cynthia Cai
Viva BioInnovator
Valerie Calenda
Mérieux Equity Partners
Anke Cassing
High-Tech Gründerfonds
Jeremy Chang
Benjamin Chen
Panacea Ventures
Kenneth Chew
Vickers Venture Partners
Poh Hui Chia
Vickers Venture Partners
Chinmay Chinmay
Elizabeth Cho-Fertikh
Meda Angels
Michel Chu
Acorn Campus Taiwan
Pablo Cironi
Caixa Capital Risc
Barbara Clarke
Astia Angels
Darren Cooke
Life Science Angels
Peter Crane
Outsized Ventures
David Crean
Mesa Verde Venture Partners
Ruchi Dana
Dana Group
Aldemar Degroot
Niels Emmerich
AbbVie Inc.
Bettina Ernst
Jemima Escamilla
Research Corporation Technologies
Naomi Fried
Ambit Health Ventures
Ryo Fujinami
Shinsei Capital Partners
Robert Garber
7wire Ventures
Gary Gershony
BayMed Venture Partners
Tom Gibbs
Debiopharm Innovation Fund
Sam Goldberger
Ambit Health Ventures
Gage Greening
Medical Technology Enterprise Consortium (MTEC)
Bryan Grulke
Volcano Capital
Brian Hakim
Elaine Hamm
Ascend BioVentures
Z Haroon
Julz Co LLC
Christopher Haskell, Ph.D.
Michelle Ho
5AM Ventures
Vivien Ho
Pear Ventures
Alan Hochberg
Dave Hood
Medical Technology Enterprise Consortium (MTEC)
Dmitrij Hristodorov
Forbion Capital Partners
Adam Hunke
Banner Venture Group
Tomoko Ishikura
Kicker Ventures
Mishael Zohar
OrbiMed Advisors LLC
I-Chien Jan
Hukui Bio
Allan Johnston
Synergy Ventures
Rick Jones
Patrick Keenan
Prevail Partners
Faisal Khan
John Kim
Aphelion Capital, LLC
Kristin King
Boston Harbor Angels
Merom Klein
Keiretsu Forum
Pascal Krotee
RiverVest Venture Partners
Dmitry Kuzmin
4Bio Capital Partners
Sebastien Latapie
Dynamk Capital
Zachary Leach
Catalyst Health Ventures
Carla Lema Tomé
Otsuka Pharmaceutical
Elliot Levy
DreamIt Health
George Li
Proxima Ventures
Yatong Li
Sixty Degree Capital
Xinhong Lim
Vickers Venture Partners
Debbie Lin
Boehringer Ingelheim Venture Fund
Don Lin
Guoqian Venture Capital Investment
Henry Lu
China Merchants Capital
Benedikt Luhmann
VI Partners
Marc Martin-Casas
Illumina Accelerator
Tai Mei
Meda Angels
Andy Merken
Burns & Levinson
Wouter Meuleman
Illumina Ventures
Junaid Mian
Sergio Montero
Start-Up Chile
Walter Moos
Pandect Bioventures
Anesa Mulabecirovic
Hadean Ventures
Kim Nearing
Justin Norden
GSR Ventures
Cédric Odje
Debiopharm Innovation Fund
Michael O’Donnell
Life Science Angels
Marion Paolini
Nami Park
Life Science Angels
Francoise Perron-Sierra
Dave Pinkowitz
AnPac Bio
Rohit Pratap Singh
Xeraya Capital
Mark Ralph
Boehringer Ingelheim Venture Fund
Varun Ramdevan
Johnson & Johnson Innovation
iGan Partners Employees, Location, Careers | LinkedIn
David Ramos
iGan Partners
Richard Reschen
Stella Robertson
Bios Partners
Mel Rothberg
Mira Life Science Ventures
Nikhil Sadhwani
Individual Angel
Caroline Sai
Angels Santé
Christina Salys
Intuitive Surgical
Diana Saraceni
Panakes Partners
Barbara Schilberg
Steve Seuntjens
Personal Health Solutions
Bryan Shao
Keiretsu Forum
Niels Sharman
High-Tech Gründerfonds
Megan Shaw
Innovation Works
David Siet
Amzak Health
Mira Sirotic
Keiretsu Forum
Catello Somma
TVM Capital Life Science
Jill Sorensen
Medical Technology Enterprise Consortium (MTEC)
Adarsh Sowcar
Karen Spilizewski
RiverVest Venture Partners
Mark Springel
Vida Ventures
Sanjay Srinivasan
Accent Advisors
Eran Steinberg
Imaging Arts
Kevin Sterling
Keiretsu Forum
Weiyong Sun
Daiichi Sankyo
Ben Sun
Sand Hill Angels
Haolin Sung
Chaperone Investment
Gayathri Swaminath
GreenFire Bio, LLC
Mayank Taneja
OSF Healthcare Ventures
Mark Tang
Good Health Capital
Liz Todia
Mutual Capital Partners
Gadi Toren
Robert Bosch Venture Capital
Bill Trainor
Mutual Capital Partners
Robert Tucci
Texas Halo Fund
Thomas Vogelsong
KYTO Technology and Life Science
Tad Weems
Agilent Technologies
Scott Weiner
Amzak Health
Travis Whitfill
Bios Partners
Thierry Wurch
Ipsen S.A.
Jonathan Yeh
Saisei Ventures
John Yianni
Alicia Yin
6 Dimensions Capital
Derek Yuan
LYFE Capital
Yanxiang Zhou
Illumina Ventures
Anthony Zlaket
UnityPoint Health Ventures


LSN Global Fundraising Bootcamp Series: Branding & Messaging for Fundraising

14 Oct

By Gregory Mannix, Vice President International Business Development, General Manager Europe, LSN

Join us October 19, 10 AM EDT/16:00 CEST for a new edition of Life Science Nation (LSN)’s Fundraising Bootcamp series, co-organized by BioIndustry Park Silvano Fumero in Turin, Italy. The topic of focus will be the importance of communicating effectively when reaching out to potential investors and partners through clear and compelling branding and messaging.


In our last joint event for Europe, one of the key takeaways was the need to go global in early-stage fundraising. We highlighted the fact that global funding in the life sciences hit an all-time high in 2020 and is continuing to break records in 2021, but the lion’s share of deals happened in the US, followed distantly by Asia and Europe. The LSN Investor Database shows that even for a European company, there are more potential investment firms from outside of Europe than from the actual old continent itself, illustrating the need to seek global partners.

Register today to learn more about how LSN is making the world of early-stage funding a smaller place by tearing down the barriers between cross-border connections and how you can start reaching a global audience.



Crafting the Tale to Tell with Terra Bioworks

14 Oct

By Rory McCann, Marketing Manager & Conference Producer, LSN

What can often stand in the way of meaningful connection with investors is a company story, and what often stands in the way of crafting the tale you want to tell can be you. No one knows your story better than you do, which can make it difficult to tell it clearly and concisely to those who do not yet know you.

Dr. David Mead, CEO of Terra Bioworks knew all there is to know about his company and the great work they are doing, but with the help of Dennis Ford and the team at Life Science Nation, David was able to put his knowledge to work telling a meaningful story to investors interested in his company. Learn more about David’s experience with LSN’s branding and messaging team and how he leveraged this experience to make powerful connections at Digital RESI.

Do you want to put your own company story to the test? Register for Digital RESI November and save $100 on early bird rates until October 29.


RESI January 2022 to Remain Virtual

7 Oct

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the LSN Partnering Conference Series

RESI January 2022 will remain virtual for the health and safety of our global community and will not have an in-person component. RESI partnering is a powerful, valuable tool at the fingertips of fundraising executives, and the team at Life Science Nation has chosen to optimize the virtual experience, rather than limit the in-person one. Through technological advancement and a more accessible price point, the RESI partnering experience is more impactful than ever with investors, collaborators, and licensing channel partners using RESI to source, vet, and sign deals. We hope you’ll join us for another Digital RESI January and support global public health initiatives for a brighter future together.


RESI November Deadline Tomorrow

7 Oct

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN


Life Science Nation’s last conference of the year, RESI Partnering Week (RPW), November 16-18, is actively taking registrations from startup companies, investors, service providers, and more across the globe and the super early bird registration rates end this week. The conference is unique in that it features three tracks of content around drugs, devices, digital health, global investment, AI applications, and age-tech and senior care across panels, fireside chats, and workshops, as well as more Innovator’s Pitch Challenge (IPC) sessions than ever before.

Last year’s RESI November event attracted over 350+ investors across ten different categories of investors from venture capital, family office/private wealth, big pharma, large medtech, and more. Do not miss the opportunity to close off this year with another robust partnering event at an unbeatable price! Sign up by Friday, October 8 to save $200!


Confirmed Digital RESI November Investors

As of October 7


Sometimes Money Isn’t Enough

7 Oct

By Karen Deyo, Director of Investor Research, Israel BD, LSN; Gregory Mannix, Vice President International Business Development, General Manager Europe, LSN

Life Science Nation (LSN) and the Redefining Early Stage Investment (RESI) conference series are built on the belief that a startup can improve its fundraising success by partnering often and making sure that the investors and strategic partners they reach out to are a fit for their technology and stage of development. However, while fundraising is a key piece of the puzzle to achieving success, it is not the only piece.

The other pillar of the RESI conference is our service provider attendees, many of whom sponsor the events. These companies can play a crucial role in giving startups advice to navigate the complex path of taking a technology to a finished product. Simply put, a lack of funding is not the only reason a company may fail – if the company makes an early mistake through inexperience, this can cause issues down the road when they can no longer be fixed.

The service providers who attend RESI can offer valuable insight to early-stage companies based on years, and often decades, of experience working in this space. Taking the opportunity to connect with them at RESI can help a startup achieve that next milestone on the most efficient path. It is often worth the additional cost to know that it is done right and often much faster than achieved in-house.

Sponsors at RESI Partnering Week represent a wide array of valuable services that early-stage companies will benefit from, and they offer guidance and workshops at RESI. Here are some examples:

  • MWE has offered workshops on Negotiating Term Sheets—always a favorite at RESI—and on Commercialization of AI Technologies.
  • Burns & Levinson has shared guidance on such relevant topics as Intellectual Property and Cross-Border Transactions.
  • First Republic Bank discussed the wide array of services that banks can offer to startups.
  • Venture Valuation offered valuable insight on Company Valuation for Fundraising

Other sponsors can provide information on topics ranging from insurance needs for life science companies (Medmarc) to Clinical Trials in Australia (Avance Clinical) to financing of scientific equipment (Boldview Capital), to name just a few.

Aside from information and insight, the great service provider companies that come to RESI are available to help early-stage companies on the long journey to commercialization or exit. Learn more about sponsorship opportunities and how LSN’s business development team can help you reach your goals.


%d bloggers like this: